TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07903493: A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects

Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07903493 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07903493 Rescue Dossier →